Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more

Recent & Breaking News (TSXV:NGEN)

NervGen Pharma (TSXV:NGEN) awarded US$1.5M from Department of Defense

Brieanna McCutcheon  October 12, 2022

NervGen Pharma Awarded up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

Newsfile October 12, 2022

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

Newsfile September 29, 2022

NervGen Pharma (TSXV:NGEN) announces leadership changes

John Ballem  September 23, 2022

NervGen Pharma Announces Leadership Transition

Newsfile September 22, 2022

NervGen Pharma (TSXV:NGEN) appoints Dr. Matvey Lukashev as VP, Research and Preclinical Development

Shoran Devi September 12, 2022

NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development

Newsfile September 12, 2022

Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?

TheNewsWire September 8, 2022

NervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting

Newsfile September 8, 2022

NervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Update

Newsfile August 10, 2022

NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conference

Newsfile August 2, 2022

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University

Business Wire July 28, 2022

NervGen Pharma (TSXV: NGEN) (OTCQX: NGENF) grants stock options

Sabrina Cuthbert July 15, 2022

NervGen Pharma Grants Stock Options

Newsfile July 15, 2022

NervGen Pharma (TSXV:NGEN) closes US$15M private placement

John Ballem  July 14, 2022

NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors

Newsfile July 14, 2022

NervGen Pharma Provides Update on Closing of Private Placement

Newsfile July 11, 2022

NervGen Pharma (TSXV:NGEN) announces US$15M private placement

John Ballem  June 30, 2022

NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement

Newsfile June 30, 2022

NervGen Pharma Grants Stock Options

Newsfile May 31, 2022